IctusNCT07196878
Percutaneous Ultrasound-guided Neuromodulation to Improve Gait Rehabilitation in Patients Who Have Suffered a Stroke.
A study testing Ultrasound-Guided Percutaneous Neuromodulation in people with Ictus and Gait Disorders, Neurologic, run by Alejandro Martín García at 1 site in Spain.
Trial summary
The goal of this clinical trial is to learn if percutaneous ultrasound-guided neuromodulation (NMP-e) can improve gait rehabilitation in adults who have suffered a stroke. The main questions it aims to answer are: Does NMP-e improve walking speed in stroke survivors? Does NMP-e enhance muscle strength, functional… Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Ictus, Gait Disorders, Neurologic
- What is being tested?
- Ultrasound-Guided Percutaneous Neuromodulation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteSpain
- Study dates
- 15 Sep 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be between 18 and 70 years of age;
- Have suffered a stroke (CVA);
- Be in the subacute or chronic phase of the disease;
- Be able to walk 10 meters without assistance from another person;
- Currently be undergoing physiotherapy with conservative techniques;
- Be able to understand the technique being applied;
- Sign the informed consent form.
Who cannot join
- Belonephobia (fear of needles);
- Allergy to needles or metals;
- Presence of uncontrolled coagulopathies;
- Presence of uncontrolled arterial disease;
- Pregnancy;
- Dermatological disorders;
Show all 9Show fewer
- Presence of diseases such as systemic inflammatory disorders (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or septic arthritis);
- Presence of diseases such as tumors, cancer, or metastases;
- Having received invasive physiotherapy treatment in the last 4 weeks.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Universidad de Zaragoza
Zaragoza, Aragon, 50009
Alejandro Martín García, +34655856799, alejandro140martin@gmail.com
About this study
Official title: Ultrasound-Guided Percutaneous Neuromodulation Protocol to Improve Gait Rehabilitation in Patients Who Have Suffered a Stroke. Clinical Trial.
The goal of this clinical trial is to learn if percutaneous ultrasound-guided neuromodulation (NMP-e) can improve gait rehabilitation in adults who have suffered a stroke. The main questions it aims to answer are:
- Does NMP-e improve walking speed in stroke survivors?
- Does NMP-e enhance muscle strength, functional mobility, reduce spasticity, improve balance, and increase health-related quality of life?
Read more
Researchers will compare the addition of NMP-e to conventional physiotherapy versus conventional physiotherapy alone to see if the intervention provides additional benefits in gait rehabilitation and other functional outcomes.
Participants will:
- Continue their regular physiotherapy treatment consisting of passive and active-assisted mobilizations and strength exercises.
- Receive NMP-e targeting the sciatic nerve at mid-thigh and the common peroneal nerve at the fibular head (experimental group only).
- Undergo stimulation with an electrostimulator at 10 Hz for 10 seconds per trial, repeated 10 times, with intensity adjusted for comfort.
- Be evaluated before the intervention, immediately after, and one week later using:
- 10-Meter Walk Test for gait speed
- Dynamometry for ankle plantarflexor and dorsiflexor strength
- Time Up and Go test for functional mobility
- Modified Modified Ashworth Scale for spasticity
- Berg Balance Scale for balance
- EuroQoL-5 Dimensions for health-related quality of life
Participants must be adults aged 18-70, able to walk 10 meters without assistance, currently receiving physiotherapy, and able to provide informed consent. Key exclusions include pregnancy, bleeding disorders, needle allergies, systemic inflammatory disorders, or recent invasive physiotherapy.
This randomized controlled trial will be conducted at ATECE, a Spanish association dedicated to the care and rehabilitation of individuals with acquired brain injury, where participants will be recruited and receive their interventions. The study aims to evaluate the potential of NMP-e as an adjunctive therapy for improving gait and related functional outcomes in subacute and chronic stroke patients.
Read the detailed description
This study is designed to evaluate the effectiveness of ultrasound-guided percutaneous neuromodulation (PNM) combined with conventional physiotherapy in improving gait and functional outcomes in adults recovering from subacute to chronic stroke. Stroke is a leading cause of long-term disability worldwide, frequently resulting in impaired motor control, reduced muscle strength, altered gait patterns, and decreased functional independence. Conventional physiotherapy remains the cornerstone of post-stroke rehabilitation, focusing on exercises to enhance strength, coordination, balance, and mobility. However, recovery is often incomplete, and additional interventions that can augment neuroplasticity and motor recovery are critically needed.
Ultrasound-guided PNM is a minimally invasive technique that involves targeted electrical stimulation of peripheral nerves via a fine needle under ultrasound guidance. By stimulating the sciatic and deep peroneal nerves, PNM may enhance neuromuscular activation, improve muscle recruitment, reduce spasticity, and facilitate motor relearning. This trial seeks to determine whether integrating PNM with standard physiotherapy produces greater improvements in walking speed, lower limb strength, balance, and functional mobility compared to physiotherapy alone.
A total of 30 participants aged 18-70 years who have experienced a stroke at least three months prior and are capable of walking a minimum of 50 meters with or without assistive devices will be enrolled. Participants will be randomly assigned in a 1:1 ratio to either the experimental group, receiving ultrasound-guided PNM plus physiotherapy, or the control group, receiving physiotherapy alone. The intervention will be delivered over multiple sessions following a standardized protocol. In the experimental group, the PNM sessions will target the sciatic and deep peroneal nerves of the affected limb, using a pre-determined stimulation frequency and intensity individualized to each participant's tolerance. Physiotherapy sessions will include strength training, gait training, balance exercises, and functional mobility tasks, applied consistently across both groups.
Outcomes will be assessed at baseline, immediately post-intervention, and one week after the last treatment session to capture both immediate and short-term effects. The primary outcome measure is walking speed, assessed using the 10-Meter Walk Test, a validated and widely used metric of functional gait performance. Secondary outcomes include lower limb muscle strength (ankle dorsiflexors and plantarflexors) measured with handheld dynamometry, spasticity assessed by the Modified Modified Ashworth Scale, functional mobility evaluated using the Timed Up and Go test, balance assessed with the Berg Balance Scale, and health-related quality of life measured with the EQ-5D questionnaire.
Data will be analyzed using mixed linear and logistic regression models, accounting for repeated measures and individual variability. Safety and tolerability will be closely monitored throughout the study, with adverse events recorded and managed according to established protocols. Participants will provide informed consent and retain the right to withdraw from the study at any time without any consequences to their ongoing care.
This trial aims to provide robust evidence regarding the potential additive benefits of ultrasound-guided PNM to conventional physiotherapy in post-stroke rehabilitation. Demonstrating a significant improvement in gait, muscle strength, and functional independence could support the adoption of PNM as a novel, evidence-based adjunct therapy for stroke survivors, potentially enhancing long-term outcomes and quality of life.
- Conditions
- Ictus, Gait Disorders, Neurologic
- Being tested
- Ultrasound-Guided Percutaneous Neuromodulation
- Keywords
- ICTUS, Gait disorder, Ultrasound guided neuromodulation
- Medical subject headings
- Gait Disorders, Neurologic, Mobility Limitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound-Guided Percutaneous NeuromodulationOther
An ultrasound-guided puncture is performed to place one needle near the sciatic nerve and another near the peroneal nerve. Then, an electrical stimulus at 10 Hz is applied for 10 seconds, repeated 10 times.
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound-Guided Percutaneous Neuromodulation | Experimental | Ultrasound-guided percutaneous neuromodulation is performed 10 times, each lasting 10 seconds with 10-second rest intervals. Receives: Other: Ultrasound-Guided Percutaneous Neuromodulation |
| Control group | No intervention | Control group that does not receive the intervention; it is used solely for comparison. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Velocidad
The speed will be measured using the 10-Meter Walk Test.
Measured: This variable will be measured before, immediately after, and one week later.
Secondary outcomes (5)
Isometric strength of the ankle plantarflexor and dorsiflexor muscles.
The strength of the ankle flexor and extensor muscles will be measured using a dynamometer.
Measured: It will be measured before, immediately after, and one week following the intervention.
Functional mobility will be assessed using the Timed Up and Go (TUG) test.
The participant will be seated in a chair until they hear the evaluator's signal to start the test. The participant must stand up, walk a total of 3 meters in a straight line, return to the chair, and resume the starting position. Three measurements will be taken, and the best result will be considered the most accurate.
Measured: The measurement will be taken before, immediately after, and one week following the intervention.
Spasticity will be assessed using the Modified Modified Ashworth Scale (MMAS).
Muscle tone of the hamstring and anterior tibial muscles will be measured.
Measured: It will be measured before, immediately after, and one week following the intervention.
Balance will be assessed using the Berg Balance Scale (BBS).
Participants will perform a total of 14 tasks, which include: standing up from a seated position, maintaining a standing position without support, sitting without leaning the back while keeping the feet on the floor or on a footrest, sitting down from a seated position, performing two transfers from one chair to another and returning to the first chair, maintaining a standing position without support with eyes closed, maintaining a standing position without support with feet together, reaching forward with an extended arm, picking up an object from the floor while standing, turning the head backward over the right and left shoulders while standing, performing a 360º turn, alternately stepping one foot onto a step or footrest while standing without support, maintaining a standing position without support with one foot forward, and maintaining a one-legged stance.
Measured: It will be measured before, immediately after, and one week following the intervention.
Health-related quality of life will be assessed using the EuroQoL-5 Dimensions (EQ-5D) scale.
It consists of two main parts: the first is a description of the individual's health across five domains, and the second is the Visual Analog Scale (VAS), which assesses the individual's overall perception of health. The first part of the scale evaluates: a) mobility; b) self-care; c) usual activities; d) pain/discomfort; e) anxiety/depression. Each domain has five response levels describing the degree of difficulty experienced by the individual, ranging from no difficulty to extreme difficulty. The second part is assessed using a line on which the individual marks their overall perception of health at the time of the assessment, with one end representing "best imaginable health" and the other end representing "worst imaginable health."
Measured: The scale will be administered before, immediately after, and one week following the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start15 Sep 2025
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IctusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- An intervention group receiving the procedure in addition to their usual treatment is compared with a control group that receives only their usual treatment (the same as the intervention group).
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alejandro Martín García
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Alejandro Martín García, Universidad de Zaragoza
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07196878
- Sponsor's protocol ID
- C.I. PI25/059
- Status last verified
- Jun 2026
- First submitted
- 19 Sep 2025
- Last updated
- 12 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-Guided Percutaneous Neuromodulation Protocol to Improve Gait Rehabilitation in Patients Who Have Suffered a Stroke. Clinical Trial.
- ClinicalTrials.gov ID
- NCT07196878
- Acronym / sponsor ID
- C.I. PI25/059
- Conditions
- Ictus, Gait Disorders, Neurologic
- Keywords
- ICTUS, Gait disorder, Ultrasound guided neuromodulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Alejandro Martín GarcíaUniversity, hospital or other
- Study start
- 15 Sep 2025 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if percutaneous ultrasound-guided neuromodulation (NMP-e) can improve gait rehabilitation in adults who have suffered a stroke. The main questions it aims to answer are:
- Does NMP-e improve walking speed in stroke survivors?
- Does NMP-e enhance muscle strength, functional mobility, reduce spasticity, improve balance, and increase health-related quality of life?
Researchers will compare the addition of NMP-e to conventional physiotherapy versus conventional physiotherapy alone to see if the intervention provides additional benefits in gait rehabilitation and other functional outcomes.
Participants will:
- Continue their regular physiotherapy treatment consisting of passive and active-assisted mobilizations and strength exercises.
- Receive NMP-e targeting the sciatic nerve at mid-thigh and the common peroneal nerve at the fibular head (experimental group only).
- Undergo stimulation with an electrostimulator at 10 Hz for 10 seconds per trial, repeated 10 times, with intensity adjusted for comfort.
- Be evaluated before the intervention, immediately after, and one week later using:
- 10-Meter Walk Test for gait speed
- Dynamometry for ankle plantarflexor and dorsiflexor strength
- Time Up and Go test for functional mobility
- Modified Modified Ashworth Scale for spasticity
- Berg Balance Scale for balance
- EuroQoL-5 Dimensions for health-related quality of life
Participants must be adults aged 18-70, able to walk 10 meters without assistance, currently receiving physiotherapy, and able to provide informed consent. Key exclusions include pregnancy, bleeding disorders, needle allergies, systemic inflammatory disorders, or recent invasive physiotherapy.
This randomized controlled trial will be conducted at ATECE, a Spanish association dedicated to the care and rehabilitation of individuals with acquired brain injury, where participants will be recruited and receive their interventions. The study aims to evaluate the potential of NMP-e as an adjunctive therapy for improving gait and related functional outcomes in subacute and chronic stroke patients.
Detailed description
This study is designed to evaluate the effectiveness of ultrasound-guided percutaneous neuromodulation (PNM) combined with conventional physiotherapy in improving gait and functional outcomes in adults recovering from subacute to chronic stroke. Stroke is a leading cause of long-term disability worldwide, frequently resulting in impaired motor control, reduced muscle strength, altered gait patterns, and decreased functional independence. Conventional physiotherapy remains the cornerstone of post-stroke rehabilitation, focusing on exercises to enhance strength, coordination, balance, and mobility. However, recovery is often incomplete, and additional interventions that can augment neuroplasticity and motor recovery are critically needed.
Ultrasound-guided PNM is a minimally invasive technique that involves targeted electrical stimulation of peripheral nerves via a fine needle under ultrasound guidance. By stimulating the sciatic and deep peroneal nerves, PNM may enhance neuromuscular activation, improve muscle recruitment, reduce spasticity, and facilitate motor relearning. This trial seeks to determine whether integrating PNM with standard physiotherapy produces greater improvements in walking speed, lower limb strength, balance, and functional mobility compared to physiotherapy alone.
A total of 30 participants aged 18-70 years who have experienced a stroke at least three months prior and are capable of walking a minimum of 50 meters with or without assistive devices will be enrolled. Participants will be randomly assigned in a 1:1 ratio to either the experimental group, receiving ultrasound-guided PNM plus physiotherapy, or the control group, receiving physiotherapy alone. The intervention will be delivered over multiple sessions following a standardized protocol. In the experimental group, the PNM sessions will target the sciatic and deep peroneal nerves of the affected limb, using a pre-determined stimulation frequency and intensity individualized to each participant's tolerance. Physiotherapy sessions will include strength training, gait training, balance exercises, and functional mobility tasks, applied consistently across both groups.
Outcomes will be assessed at baseline, immediately post-intervention, and one week after the last treatment session to capture both immediate and short-term effects. The primary outcome measure is walking speed, assessed using the 10-Meter Walk Test, a validated and widely used metric of functional gait performance. Secondary outcomes include lower limb muscle strength (ankle dorsiflexors and plantarflexors) measured with handheld dynamometry, spasticity assessed by the Modified Modified Ashworth Scale, functional mobility evaluated using the Timed Up and Go test, balance assessed with the Berg Balance Scale, and health-related quality of life measured with the EQ-5D questionnaire.
Data will be analyzed using mixed linear and logistic regression models, accounting for repeated measures and individual variability. Safety and tolerability will be closely monitored throughout the study, with adverse events recorded and managed according to established protocols. Participants will provide informed consent and retain the right to withdraw from the study at any time without any consequences to their ongoing care.
This trial aims to provide robust evidence regarding the potential additive benefits of ultrasound-guided PNM to conventional physiotherapy in post-stroke rehabilitation. Demonstrating a significant improvement in gait, muscle strength, and functional independence could support the adoption of PNM as a novel, evidence-based adjunct therapy for stroke survivors, potentially enhancing long-term outcomes and quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- An intervention group receiving the procedure in addition to their usual treatment is compared with a control group that receives only their usual treatment (the same as the intervention group).
| Arm | Type | Receives |
|---|---|---|
| Ultrasound-Guided Percutaneous Neuromodulation | Experimental | Other: Ultrasound-Guided Percutaneous NeuromodulationUltrasound-guided percutaneous neuromodulation is performed 10 times, each lasting 10 seconds with 10-second rest intervals. |
| Control group | No intervention | –Control group that does not receive the intervention; it is used solely for comparison. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Be between 18 and 70 years of age;
- Have suffered a stroke (CVA);
- Be in the subacute or chronic phase of the disease;
- Be able to walk 10 meters without assistance from another person;
- Currently be undergoing physiotherapy with conservative techniques;
Key exclusion criteria (9 listed)
- Belonephobia (fear of needles);
- Allergy to needles or metals;
- Presence of uncontrolled coagulopathies;
- Presence of uncontrolled arterial disease;
- Pregnancy;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound-Guided Percutaneous NeuromodulationAn ultrasound-guided puncture is performed to place one needle near the sciatic nerve and another near the peroneal nerve. Then, an electrical stimulus at 10 Hz is applied for 10 seconds, repeated 10 times. | Other | Ultrasound-Guided Percutaneous Neuromodulation |
Primary outcome
Velocidad
Time frame: This variable will be measured before, immediately after, and one week later.
The speed will be measured using the 10-Meter Walk Test.
5 secondary outcomes
Isometric strength of the ankle plantarflexor and dorsiflexor muscles.
Time frame: It will be measured before, immediately after, and one week following the intervention.
Functional mobility will be assessed using the Timed Up and Go (TUG) test.
Time frame: The measurement will be taken before, immediately after, and one week following the intervention.
Spasticity will be assessed using the Modified Modified Ashworth Scale (MMAS).
Time frame: It will be measured before, immediately after, and one week following the intervention.
Balance will be assessed using the Berg Balance Scale (BBS).
Time frame: It will be measured before, immediately after, and one week following the intervention.
Health-related quality of life will be assessed using the EuroQoL-5 Dimensions (EQ-5D) scale.
Time frame: The scale will be administered before, immediately after, and one week following the intervention.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Ictus
Not yet recruitingObservational study
The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain
Retinal Artery Occlusion, Central Retinal Artery Occlusion
Recruiting
Informational Needs of Caregivers of Patients With Neuromotor Disease in Rehabilitation Hospitalization: Validation Study of the QBI-R/V
Neuro-Degenerative Diseases, Care Givers
Recruiting
Music Therapy in Post-Stroke Patients: A Clinical Trial
CVA (Cerebrovascular Accident), Ictus
Not yet recruiting
Effectiveness of Laser Visual Feedback in Postural Control After a Stroke
Ictus, Convalescence
RecruitingObservational study
Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy.
Cerebral Amyloid Angiopathy, CAA - Cerebral Amyloid Angiopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound-Guided Percutaneous Neuromodulation in people with Ictus and Gait Disorders, Neurologic, run by Alejandro Martín García at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alejandro Martín García (+34655856799, alejandro140martin@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Velocidad (time frame: This variable will be measured before, immediately after, and one week later.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.